Viridian Therapeutics Inc
VRDNHealthcare|Biotechnology|USA
$19.75
-0.46 (-2.28%)
Tangible Book
$4.92
Upcoming Data Readouts (0)
No upcoming completion dates found in active trials.
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2026
P3
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Mar 2026
P3
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398Feb 2026
P3
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411